Cargando…

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib

In the past decade, molecular-targeted drugs have been focused upon for the treatment of cancer. In 2002, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor became available in Japan for the treatment of non-small cell lung cancer (NSCLC). Over 80% of selected patients,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Araki, Takuya, Yashima, Hideaki, Shimizu, Kimihiro, Aomori, Tohru, Hashita, Tadahiro, Kaira, Kyoichi, Nakamura, Tomonori, Yamamoto, Koujirou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520446/ https://www.ncbi.nlm.nih.gov/pubmed/23239933 http://dx.doi.org/10.4137/CMO.S7340

Ejemplares similares

Erratum in: Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2013)

Effect of Ethanol in Paclitaxel Injections on the Ethanol Concentration in Exhaled Breath
por: Aomori, Tohru, et al.
Publicado: (2012)

Sex Differences in the Blood Concentration of Tacrolimus in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients with CYP3A5*3/*3
por: Ito, Ayano, et al.
Publicado: (2017)

Increased c‑SRC expression is involved in acquired resistance to lenvatinib in hepatocellular carcinoma
por: Takahashi, Masamitsu, et al.
Publicado: (2023)

Blood Concentration of Cabazitaxel in a Patient Whose General Condition Worsened with Concomitant Use of Clarithromycin
por: Katsumi, Shigeaki, et al.
Publicado: (2023)

Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer
por: Tsukagoshi, Mariko, et al.
Publicado: (2020)

Prognostic potential of the MDM2 309T>G polymorphism in stage I lung adenocarcinoma
por: Enokida, Yasuaki, et al.
Publicado: (2016)

Target concentration achievement for efficacy and safety of patients with osteosarcoma treated with high-dose methotrexate based on individual pharmacokinetics: A retrospective study
por: Nagamine, Ayumu, et al.
Publicado: (2022)

Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2017)

Epiregulin as a therapeutic target in non-small-cell lung cancer
por: Sunaga, Noriaki, et al.
Publicado: (2015)

The role of [(18)F]fluorodeoxyglucose positron emission tomography in thymic epithelial tumors
por: Kaira, Kyoichi, et al.
Publicado: (2011)

Prognostic value of metabolic tumor volume of pretreatment (18)F-FAMT PET/CT in non-small cell lung Cancer
por: Kumasaka, Soma, et al.
Publicado: (2018)

Risk of Falling and Hypnotic Drugs: Retrospective Study of Inpatients
por: Obayashi, Kyoko, et al.
Publicado: (2013)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Choroidal Metastasis of Non-Small Cell Lung Cancer That Responded to Gefitinib
por: Shimomura, Iwao, et al.
Publicado: (2013)

Impact of the Bim Deletion Polymorphism on Survival Among Patients With Completely Resected Non–Small-Cell Lung Carcinoma
por: Atsumi, Jun, et al.
Publicado: (2015)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study
por: Egami, Saeka, et al.
Publicado: (2021)

Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study
por: Egami, Saeka, et al.
Publicado: (2021)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
por: Sudo, Makoto, et al.
Publicado: (2013)

The Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India
por: Mehta, Asmita Anilkumar, et al.
Publicado: (2013)

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
por: Carotenuto, Pietro, et al.
Publicado: (2011)

Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Dilemma Concerning the Differential Diagnosis of Hematological Malignancy and Bone Metastasis Arising from Lung Cancer
por: Kaira, Kyoichi
Publicado: (2022)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis
por: Yi, Min, et al.
Publicado: (2023)

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
por: Tiseo, M, et al.
Publicado: (2010)

Management of patients with advanced non-small cell lung cancer: role of gefitinib
por: Velcheti, Vamsidhar, et al.
Publicado: (2010)

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer
por: Wang, Hsian-Yu, et al.
Publicado: (2016)

Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer
por: Lu, Xiangdong, et al.
Publicado: (2021)

Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine
por: Bilguun, Erkhem-Ochir, et al.
Publicado: (2020)

Pharmacokinetics of Gefitinib in a Patient with Non-Small Cell Lung Cancer Undergoing Continuous Ambulatory Peritoneal Dialysis
por: Yamaguchi, Teppei, et al.
Publicado: (2015)

Course of postoperative relapse in non‐small cell lung cancer is strongly associated with post‐progression survival
por: Imai, Hisao, et al.
Publicado: (2021)

Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation
por: Yamaguchi, Ou, et al.
Publicado: (2020)

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
por: Nio, Yuta, et al.
Publicado: (2022)

Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin
por: Sakurai, Reiko, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3ampjv4fag6ufo8c032m5ft9o5